Ongoing Clinical Trials for Perinatal Depression
There are currently 2 clinical trials investigating new approaches to prevent and treat perinatal depression in women after childbirth. These studies are examining the effectiveness of iron supplementation and hormone therapy in reducing the risk of depression during the postpartum period.
Clinical trial locations
- Denmark
- France
Perinatal depression is a serious condition that can affect women during pregnancy or after giving birth. The following clinical trials are exploring different treatment approaches to help prevent or manage this condition in new mothers.
Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia
This trial is being conducted in France and focuses on women who have delivered their babies by caesarean section and developed moderate anemia afterward. The study examines whether treating iron deficiency can help reduce the risk of postpartum depression.
Who can participate:
Women who are eligible for this study must be at least 18 years old and have given birth by caesarean delivery after at least 32 weeks of pregnancy. Within 72 hours after delivery, their hemoglobin levels must be between 8.0 and 10.0 grams per deciliter, indicating moderate anemia. Additionally, participants must have low iron storage levels, shown by a ferritin level of 100 nanograms per milliliter or less, or a transferrin saturation of 20% or less. Women must be hospitalized in the postpartum maternity ward and have national social security coverage. They must also have a mood assessment score below 11 on the Edinburgh Postpartum Depression Scale in the immediate postpartum period.
Who cannot participate:
Women who did not deliver by caesarean section are excluded from the study. Those who do not have moderate postpartum iron deficiency anemia, meaning their blood levels or iron measures are outside the specified ranges, cannot participate. The study is limited to women within a certain age range, and men are not included.
What the trial involves:
The main goal of this study is to determine whether treating anemia with iron supplementation can reduce the occurrence of postpartum depression at 8 weeks after delivery. Researchers are comparing two different methods of iron treatment: intravenous iron, which is delivered directly into the bloodstream through a vein, and oral iron, which is taken by mouth in tablet or capsule form.
Investigational treatments:
The trial is testing both intravenous iron and oral iron treatments. Intravenous iron provides a quick way to increase iron levels in the body, which may help women recover more rapidly from anemia and potentially reduce depression risk. Oral iron supplements work more gradually by being absorbed through the digestive system. The specific intravenous product used is Ferinject, which contains ferric carboxymaltose, while the oral treatments include Timoferol in various forms containing ferrous sulfate and ascorbic acid.
Study on Using Estradiol to Prevent Postpartum Depression in Women with a History of the Condition
This trial is taking place in Denmark and investigates whether using a hormone patch immediately after childbirth can prevent postpartum depression in women who have experienced this condition before.
Who can participate:
Women between the ages of 18 and 45 who are in the third trimester of pregnancy may be eligible for this study. The key requirement is having a history of perinatal depression, which means having experienced depression during pregnancy or within six months after giving birth in the past. This includes women who had a previous depressive episode during or after pregnancy that was confirmed by a healthcare professional.
Who cannot participate:
Women with other serious medical conditions that could interfere with the study are not eligible. Those currently taking medications that might affect the study results, or who have a history of severe allergic reactions to medications, cannot participate. Women who are already participating in another clinical trial, have a history of substance abuse, or have psychiatric disorders other than postpartum depression are also excluded. Additionally, women who become pregnant again during the study period or have any condition that the study doctor believes makes participation unsafe cannot take part.
What the trial involves:
The study aims to determine whether short-term treatment with estradiol, a form of the hormone estrogen, can prevent depressive episodes in women at high risk for postpartum depression. Participants will receive treatment through a transdermal patch called Vivelle Dot, which releases estradiol through the skin over 24 hours. The treatment begins on the day of delivery and continues for 21 days. Some participants will receive a placebo patch instead, which contains no active medication, to allow researchers to compare the effectiveness of estradiol. Women will be monitored for signs of depression from two weeks to six months after giving birth.
Investigational treatment:
The hormone being tested is estradiol, which is a naturally occurring form of estrogen. The idea behind this treatment is that hormonal changes after childbirth can sometimes trigger mood disorders, and providing estradiol might help stabilize mood and prevent depression. The hormone works by interacting with estrogen receptors in the brain, which can influence mood and emotional regulation. By maintaining more stable hormone levels during the immediate postpartum period, researchers hope to reduce the risk of depression in women who are vulnerable to this condition.
Summary
These two clinical trials represent different approaches to addressing perinatal depression. The French study focuses on the potential connection between iron deficiency anemia and postpartum depression, exploring whether correcting anemia through either intravenous or oral iron supplementation might reduce depression risk. This approach is particularly relevant for women who have undergone caesarean delivery and developed moderate anemia.
The Danish study takes a hormonal approach, investigating whether estradiol patches used immediately after birth can prevent depression in women with a history of the condition. This represents a preventive strategy targeting women at known high risk.
Both trials are examining important aspects of maternal mental health during the vulnerable postpartum period. While one trial focuses on women who have already developed anemia after caesarean delivery, the other targets prevention in women with a previous history of perinatal depression. These studies may provide valuable insights into different pathways for reducing the burden of postpartum depression in new mothers.